Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...

The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation. About Taletrectinib Taletrectinib is an oral, potent, central nervous system-active, ...

SAN DIEGO--(BUSINESS WIRE)--Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a ...

BOCA RATON, Fla., August 28, 2025--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered oncology clinical trial matching, today announced the launch of its new key feature on the Patient Connect app.

This ambitious program leverages Massive Bio’s AI capabilities and Trial Command Center to significantly accelerate oncology clinical research and bring clinical trial access to the masses NEW ...

Massive Bio, a cancer patient matchmaker, has been selected by the Precision Cancer Consortium to help identify potential candidates for clinical trials. The consortium, founded in 2022, is focused on ...

Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison ...